| Kyle Mccormack, PA-C | |
|
1 Cellini Pl Ste 102, West Haven, CT 06516-1666 | |
| (203) 932-6481 | |
| (203) 932-4051 |
| Full Name | Kyle Mccormack |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 13 Years |
| Location | 1 Cellini Pl Ste 102, West Haven, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669751178 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | 002598 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Middlesex Hospital | Middletown, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Middlesex Hospital | 5092611731 | 202 |
News Archive
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
The growing number of Americans with cardiovascular disease has caused a heightened sensitivity in the evaluation of chest pain. In a study published in the April issue of Mayo Clinic Proceedings researchers reported that patients dismissed from the hospital with noncardiac chest pain continue to experience cardiac events, which may highlight a need for more aggressive cardiovascular risk factor management in this population.
Think First announced today that the Hospital of Saint Raphael (HSR) has successfully implemented Think First's recommendation to centralize patient scheduling and registration for their ambulatory clinics. The Hospital of Saint Raphael has worked closely with Think First consultants to execute this plan and has seen immediate results.
RNA interference (RNAi) represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing the state-of-the-art and potential therapeutic applications of RNAi and microRNAs will begin with two review papers in the January 2008 issue (Volume 19, Number 1) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.
In April, San Francisco-based primary care company One Medical revealed an eye-popping compensation package for its chief executive and chairman, Amir Dan Rubin. His $199 million payday, particularly noteworthy at a company that has yet to turn a profit, made Rubin the second-highest-paid CEO in the United States last year — but only on paper.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kyle Mccormack, PA-C 20 York Street, Cb-2041, New Haven, CT 06510-3220 Ph: (203) 688-4748 | Kyle Mccormack, PA-C 1 Cellini Pl Ste 102, West Haven, CT 06516-1666 Ph: (203) 932-6481 |
News Archive
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
The growing number of Americans with cardiovascular disease has caused a heightened sensitivity in the evaluation of chest pain. In a study published in the April issue of Mayo Clinic Proceedings researchers reported that patients dismissed from the hospital with noncardiac chest pain continue to experience cardiac events, which may highlight a need for more aggressive cardiovascular risk factor management in this population.
Think First announced today that the Hospital of Saint Raphael (HSR) has successfully implemented Think First's recommendation to centralize patient scheduling and registration for their ambulatory clinics. The Hospital of Saint Raphael has worked closely with Think First consultants to execute this plan and has seen immediate results.
RNA interference (RNAi) represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing the state-of-the-art and potential therapeutic applications of RNAi and microRNAs will begin with two review papers in the January 2008 issue (Volume 19, Number 1) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.
In April, San Francisco-based primary care company One Medical revealed an eye-popping compensation package for its chief executive and chairman, Amir Dan Rubin. His $199 million payday, particularly noteworthy at a company that has yet to turn a profit, made Rubin the second-highest-paid CEO in the United States last year — but only on paper.
› Verified 5 days ago
Stephan Anton Bayer, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 205 Elm St Apt 5, West Haven, CT 06516 Phone: 719-287-6053 | |
Courtney G Moller, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 950 Campbell Ave, Gec240, West Haven, CT 06516 Phone: 203-932-5711 | |
Mr. Peter Francis Lazzarotti, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 950 Campbell Ave, West Haven, CT 06516 Phone: 203-932-5711 | |
Kaitlin Coyle, Physician Assistant Medicare: Medicare Enrolled Practice Location: 286 Richmond Ave, West Haven, CT 06516 Phone: 203-824-8091 | |
Ms. Tzipporah Jael Vannorman, MPAS, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 950 Campbell Ave, Unit T3w, West Haven, CT 06516 Phone: 203-932-5711 | |
Mary E Gawron, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 950 Campbell Ave, West Haven, CT 06516 Phone: 203-932-5711 | |
Ms. Elizabeth S. Auld, PA Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 950 Campbell Ave, West Haven, CT 06516 Phone: 203-932-5711 Fax: 203-934-3457 |